Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Syntara Limited ( (AU:SNT) ) has issued an update.
Syntara has reported a pivotal quarter marked by the expansion of its lead asset amsulostat into additional blood cancer indications, including the launch of the Phase 2 MESSAGE trial in transfusion‑dependent low- and intermediate‑risk myelodysplastic syndromes in Australia and further validation via European orphan drug status in myelofibrosis, alongside a new pancreatic cancer collaboration with the Garvan Institute. Across its broader pipeline, the company advanced SNT-4728 to full recruitment in a Phase 2 iRBD trial with data due in 2026, progressed topical anti‑fibrotic SNT‑9465 into a sternotomy scar study, and ended the quarter with a pro forma cash balance of $12.3 million, setting up 2026 as a defining year with multiple clinical read‑outs that could materially influence its valuation and strategic options.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.19 price target. To see the full list of analyst forecasts on Syntara Limited stock, see the AU:SNT Stock Forecast page.
More about Syntara Limited
Syntara Limited (ASX: SNT) is a clinical-stage drug development company focused on hematology, neuroinflammatory and fibrotic diseases. Its lead asset, amsulostat (SNT-5505), targets blood cancers such as myelofibrosis and myelodysplastic syndromes, while pipeline candidates SNT-4728 and SNT-9465 address neuroinflammatory conditions linked to Parkinson’s disease and skin scarring disorders, respectively.
Average Trading Volume: 1,297,173
Technical Sentiment Signal: Sell
Current Market Cap: A$58.77M
Learn more about SNT stock on TipRanks’ Stock Analysis page.